Letter by Chen et al Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial"

Circulation. 2020 Sep 8;142(10):e127-e128. doi: 10.1161/CIRCULATIONAHA.120.046310. Epub 2020 Sep 8.

Authors

Zhi-Qing Chen¹, Feng Chen², Lang Li¹

Affiliations

¹ Departments of Cardiology (Z-Q.C., L.L.), The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
² Emergency (F.C.), The First Affiliated Hospital of Guangxi Medical University, Nanning, China.

PMID: 32897750
DOI: 10.1161/CIRCULATIONAHA.120.046310

No abstract available

Publication types

Letter
Comment

MeSH terms

Atrial Fibrillation* / diagnosis
Atrial Fibrillation* / drug therapy
Atrial Fibrillation* / epidemiology
Benzhydryl Compounds / adverse effects
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / diagnosis
Diabetes Mellitus, Type 2* / drug therapy
Glucosides / adverse effects
Humans

Substances

Benzhydryl Compounds
Glucosides
dapagliflozin